Advertisement

International Symposium on Adriamycin

Milan, 9th-10th September, 1971

  • Stephen K. Carter
  • A. Di Marco
  • M. Ghione
  • I. H. Krakoff
  • G. Mathé

Table of contents

  1. Front Matter
    Pages I-VIII
  2. Short Summary of the Informal Meeting Preceeding the Adriamycin Symposium

    1. Stephen K. Carter, A. Di Marco, M. Ghione, I. H. Krakoff, G. Mathé
      Pages 1-7
  3. Chemistry of Adriamycin

    1. Front Matter
      Pages 9-9
    2. F. Arcamone, G. Cassinelli, G. Franceschi, S. Penco, C. Pol, S. Redaelli et al.
      Pages 9-22
  4. Activity at Cell Level

  5. Activity against Experimental Tumors

  6. Pharmacology and Pharmacokinetics

    1. Front Matter
      Pages 96-96
    2. E. Arena, N. D’Alessandro, L. Dusonchet, N. Gebbia, F. Gerbasi, R. Sanguedolce et al.
      Pages 96-116
    3. D. W. Yesair, M. A. Asbell, R. Bruni, F. J. Bullock, E. Schwartzbach
      Pages 117-123
    4. Kiyoji Kimura, Hiroshi Fujita, Yasunobu Sakai
      Pages 124-134
  7. Clinical Activity and Side Effects

    1. Front Matter
      Pages 135-135
    2. H. Begemann, G. Wernekke
      Pages 135-138
    3. Gianni Bonadonna, Silvio Monfardini, Mario De Lena, Franca Fossati-Bellani, Gianni Beretta
      Pages 139-152
    4. Emil Frei III, James K. Luce, Edward Middleman
      Pages 153-160
    5. Irwin H. Krakoff
      Pages 165-167
    6. G. Mathé, J. L. Amiel, M. Hayat, F. de Vassal, L. Schwarzenberg, M. Schneider et al.
      Pages 168-172
    7. C. Rozman, E. Simó Camps, M. Ribas Mundó, F. Solsona, I. Dantart, A. Raichs et al.
      Pages 188-194
    8. Lucius F. Sinks, Engracio Cortes, Jaw J. Wang, James F. Holland
      Pages 195-203
    9. Charlotte Tan, Erlinda Etcubanas, Norma Wollner, Gerald Rosen, M. Lois Murphy, Irwin H. Krakoff
      Pages 204-212
    10. J. M. A. Whitehouse, D. Crowther, J. S. Malpas
      Pages 213-216
  8. Short Communications

    1. Front Matter
      Pages 217-217
    2. Ayhan O. Çavdar, Ü. Topuz, E. Babacan, A. Arcasoy, S. Gözdaşoğlu
      Pages 224-225
    3. H. Gerhartz
      Pages 226-228
    4. Yoshio Hara, Yuzo Kurita
      Pages 229-230
    5. Piero Lovisetto, Giuseppe Pochettino
      Pages 231-233
    6. E. Madon, P. G. Baroncelli, A. Sacerdote, P. L. Roberi
      Pages 234-235
    7. G. Marinone, E. Maiolini, E. Spadacci
      Pages 236-243
    8. K. Ota
      Pages 244-247

About these proceedings

Introduction

The impressive advances in all branches of medical science during the first half of this century with the discovery of many chemotherapeutic or immunogenic agents gave rise to brilliant achievements in the struggle against some infectious diseases and aroused in many scientists the wishful thought that drugs for cancer therapy would, soon lead to additional great success. Notwithstanding ever-increasing worldwide endeavors, the major problems in prevention or treatment of neoplastic diseases are still unsolved. The approach to the resolution of these problems follows many different pathways. Basic research tries to cast light on the genetic and biochemical processes underly­ ing cell division and differentiation as well as the interactions occurring between the cell and the oncogenic stimulus, or between the neoplastic cells and the different body systems endowed with immunological reactivity. Another line of approach, coherent with the classic basis of chemotherapy, relies upon the search for new compounds selectively blocking the multiplication of the neoplastic cells. The remarkable progress made in treating human cancer, as a result of these efforts, has been until now ascribable chiefly to the accomplishment of the chemo­ therapeutic approach. Studies on the cytostatic activity of the anthracycline antibiotics carried out over many years eventually led the investigators of Farmitalia (Milan, Italy) to discover and characterize some new compounds endowed with interesting chemotherapeutic properties against malignant neoplastic diseases.

Keywords

antibiotics cancer cancer therapy cell chemotherapy diseases infectious disease lead research therapy

Editors and affiliations

  • Stephen K. Carter
    • 1
  • A. Di Marco
    • 2
  • M. Ghione
    • 3
  • I. H. Krakoff
    • 4
  • G. Mathé
    • 5
  1. 1.Chief Cancer Therapy Evaluation Branch National Cancer InstituteBethesdaUSA
  2. 2.National Cancer InstituteMilanItaly
  3. 3.Chief, Medical Research FarmitaliaMilanItaly
  4. 4.Sloan Kettering Institute for Cancer ResearchNew YorkUSA
  5. 5.Institut de Cancérologie et d’ImmunogénétiqueVillejuifFrance

Bibliographic information

  • DOI https://doi.org/10.1007/978-3-642-95227-2
  • Copyright Information Springer-Verlag Berlin Heidelberg 1972
  • Publisher Name Springer, Berlin, Heidelberg
  • eBook Packages Springer Book Archive
  • Print ISBN 978-3-642-95229-6
  • Online ISBN 978-3-642-95227-2
  • Buy this book on publisher's site